Li Yi
Executive Director, Formulation and Process Development,
Gilead Sciences, Inc.
Li Yi is an Executive Director at Gilead Sciences, where she leads biologics pre-pivotal formulation and process development. With over 17 years of experience at Genentech, AbbVie, and Gilead, she has advanced complex biologics—including monoclonal antibodies, bispecifics, and ADCs—from early development through commercialization. Her expertise spans formulation strategy, molecule stability, and CMC acceleration. Dr. Yi actively engages in cross‑industry collaboration and brings a practical, solution‑oriented perspective to shared challenges in antibody development.
Sessions